Glaukos Corporation
GKOS
Rank in Stocks
#2039
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Share Price
$172.28
Market Cap
$10.16B
Change (1 day)
3.29%
Change (1 year)
116.79%
Country
US
Trade Glaukos Corporation (GKOS)
Category
Healthcare
Revenue for Glaukos Corporation (GKOS)
Revenue in Jun 2026 TTM: $612.84M
According to Glaukos Corporation latest financial reports the company's current revenue (TTM) is $612.84M. In 2023 the company made a revenue of $314.71M an increase over the revenue in the year 2022 that was $282.86M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Glaukos Corporation from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $612.84M | 59.81% |
| 2024 | $383.48M | 21.85% |
| 2023 | $314.71M | 11.26% |
| 2022 | $282.86M | -3.79% |
| 2021 | $294.01M | 30.70% |
| 2020 | $224.96M | -5.07% |
| 2019 | $236.98M | 30.73% |
| 2018 | $181.28M | 13.83% |
| 2017 | $159.25M | 39.21% |
| 2016 | $114.40M | 59.55% |
| 2015 | $71.70M | 57.28% |
| 2014 | $45.59M | 117.64% |
| 2013 | $20.95M | 762.33% |
| 2012 | $2.43M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $46.59B | 7,501.51% |
US
|
|
| $35.48B | 5,690.10% |
IE
|
|
| $25.84B | 4,115.95% |
US
|
|
| $21.00B | 3,326.02% |
US
|
|
| - | - |
DE
|
